Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of topical AB-SA01 in healthy adults
NCT02757755Phase 1Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AB-SA01 in Staphylococcus aureus infection (2 cohorts), sponsored by Armata Pharmaceuticals. Primary endpoints: Adverse Events at Day 14, Change from Baseline in Clinical Laboratory Tests at Day 14 and 1 more. Started May 2016; status: completed.
02
Drugs
AB-SA01
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT02757755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757755.